Poe-Hirr Hsyu1, Daniela Soriano Pignataro2, Kyle Matschke3. 1. Pfizer Inc, 10646 Science Center Drive, La Jolla, CA, 92121, USA. Poe-Hirr.Hysu@pfizer.com. 2. Pfizer Inc, Walton Oaks, Dorking Road, Surrey, KT20 7NS, UK. 3. Pfizer Inc, 500 Arcola Road, Collegeville, PA, 19426, USA.
Abstract
PURPOSE: Bosutinib, a dual Src and Abl tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia, demonstrated concentration-dependent inhibitory effects on P-glycoprotein (P-gp)-mediated digoxin efflux in vitro, suggesting that bosutinib may inhibit P-gp substrates. The effect of bosutinib on dabigatran etexilate mesylate (EM) absorption, a P-gp substrate, was evaluated. METHODS: In this open-label, randomized, single-dose, one-cohort, two-sequence, two-period crossover study, healthy, fed subjects received dabigatran EM (150 mg × 1 orally) alone or 1 h after receiving bosutinib tablets (100 mg × 5 orally). RESULTS:Dabigatran EM monotherapy and concurrent administration of dabigatran EM with bosutinib resulted in similar values for concentration time curves from time zero extrapolated to infinity (AUCinf), but slightly lower maximum plasma concentration (C max) values (AUCinf, 1182 and 1186 ng·h/mL, respectively; C max, 129.8 and 114.1 ng/mL). The time to maximum concentration for dabigatran was 2.99 and 3.99 h for combination therapy. The ratio of the adjusted geometric means (test/reference) of dabigatran AUCinf and C max (90 % confidence interval) were 101.4 % (89.6-114.9 %) and 89.7 % (77.8-103.4 %), respectively, following administration of dabigatran EM with bosutinib (test) relative to dabigatran EM administered alone (reference). Six subjects receiving combination treatment reported a total of seven adverse events (AEs) versus none for subjects receiving monotherapy alone. All AEs were mild to moderate and considered treatment related. CONCLUSION: These data demonstrate that single doses of bosutinib do not affect dabigatran exposure, suggesting that bosutinib is not a clinical inhibitor of P-gp. TRIAL REGISTRATION: ClinicalTrials.gov NCT02102633. https://clinicaltrials.gov/ct2/show/NCT02102633?term=NCT02102633&rank=1.
RCT Entities:
PURPOSE:Bosutinib, a dual Src and Abl tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia, demonstrated concentration-dependent inhibitory effects on P-glycoprotein (P-gp)-mediated digoxin efflux in vitro, suggesting that bosutinib may inhibit P-gp substrates. The effect of bosutinib on dabigatran etexilate mesylate (EM) absorption, a P-gp substrate, was evaluated. METHODS: In this open-label, randomized, single-dose, one-cohort, two-sequence, two-period crossover study, healthy, fed subjects received dabigatran EM (150 mg × 1 orally) alone or 1 h after receiving bosutinib tablets (100 mg × 5 orally). RESULTS:Dabigatran EM monotherapy and concurrent administration of dabigatran EM with bosutinib resulted in similar values for concentration time curves from time zero extrapolated to infinity (AUCinf), but slightly lower maximum plasma concentration (C max) values (AUCinf, 1182 and 1186 ng·h/mL, respectively; C max, 129.8 and 114.1 ng/mL). The time to maximum concentration for dabigatran was 2.99 and 3.99 h for combination therapy. The ratio of the adjusted geometric means (test/reference) of dabigatran AUCinf and C max (90 % confidence interval) were 101.4 % (89.6-114.9 %) and 89.7 % (77.8-103.4 %), respectively, following administration of dabigatran EM with bosutinib (test) relative to dabigatran EM administered alone (reference). Six subjects receiving combination treatment reported a total of seven adverse events (AEs) versus none for subjects receiving monotherapy alone. All AEs were mild to moderate and considered treatment related. CONCLUSION: These data demonstrate that single doses of bosutinib do not affect dabigatran exposure, suggesting that bosutinib is not a clinical inhibitor of P-gp. TRIAL REGISTRATION: ClinicalTrials.gov NCT02102633. https://clinicaltrials.gov/ct2/show/NCT02102633?term=NCT02102633&rank=1.
Authors: Marta Gromicho; Joana Dinis; Marta Magalhães; Alexandra R Fernandes; Purificação Tavares; António Laires; José Rueff; António Sebastião Rodrigues Journal: Leuk Lymphoma Date: 2011-06-12
Authors: Douglas Vivona; Carolina T Bueno; Luciene T Lima; Rosario D C Hirata; Mario H Hirata; André D Luchessi; Maria A Zanichelli; Carlos S Chiattone; Elvira M Guerra-Shinohara Journal: Blood Cells Mol Dis Date: 2011-11-30 Impact factor: 3.039
Authors: Hagop M Kantarjian; Jorge E Cortes; Dong-Wook Kim; H Jean Khoury; Tim H Brümmendorf; Kimmo Porkka; Giovanni Martinelli; Simon Durrant; Eric Leip; Virginia Kelly; Kathleen Turnbull; Nadine Besson; Carlo Gambacorti-Passerini Journal: Blood Date: 2013-12-17 Impact factor: 22.113
Authors: H Jean Khoury; Jorge E Cortes; Hagop M Kantarjian; Carlo Gambacorti-Passerini; Michele Baccarani; Dong-Wook Kim; Andrey Zaritskey; Athena Countouriotis; Nadine Besson; Eric Leip; Virginia Kelly; Tim H Brümmendorf Journal: Blood Date: 2012-02-27 Impact factor: 22.113
Authors: Douglas Vivona; Luciene Terezina Lima; Alice Cristina Rodrigues; Carolina Tosin Bueno; Greyce Kelly Steinhorst Alcantara; Luiza Saldanha Ribeiro Barros; Vania Tiestsche DE Moraes Hungria; Carlos Sérgio Chiattone; Maria DE Lourdes Lopes Ferrari Chauffaille; Elvira Maria Guerra-Shinohara Journal: Oncol Lett Date: 2014-02-07 Impact factor: 2.967
Authors: Tim H Brümmendorf; Jorge E Cortes; Hanna J Khoury; Hagop M Kantarjian; Dong-Wook Kim; Philippe Schafhausen; Maureen G Conlan; Mark Shapiro; Kathleen Turnbull; Eric Leip; Carlo Gambacorti-Passerini; Jeff H Lipton Journal: Br J Haematol Date: 2015-11-04 Impact factor: 6.998